

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELDA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mara Gordon
Date of last notice	17 November 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	1) 5 June 2019 2) 6 June 2019
No. of securities held prior to change	79,642,326
Class	Ordinary shares
Number acquired	Nil
Number disposed	1) 28,500,000 2) 7,000,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1) Non-cash, settlement of related party convertible note. Estimated valuation \$1,197,000 2) \$301,000
No. of securities held after change	44,142,326 ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	1) Off-market trade 2) Off-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELDA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jason Peterson
Date of last notice	5 February 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ul style="list-style-type: none">i. Celtic Capital Pty Ltd <The Celtic Capital A/C> (Director/Shareholder)ii. Celtic Capital Pte Ltd <Investment 1 A/C> (Director/Shareholder)iii. Professional Payment Services Pty Ltd (Director/Shareholder)iv. Wicklow Capital Pty Ltd <Tipperary A/C> (Director/Shareholder)v. Sunset Capital Management Pty Ltd <Sunset Superfund> (Director/Shareholder)vi. MJ Life Sciences Pty Ltd (Shareholder)
Date of change	<ul style="list-style-type: none">vi. 5 June 2019v. 6 June 2019
No. of securities held prior to change	<ul style="list-style-type: none">i. 11,200,000 ordinary sharesii 5,800,000 ordinary sharesiii. 538,230 ordinary sharesiv. 1,642,105 ordinary sharesv. 52,459,017 ordinary sharesv. 8,000,000 options (\$0.03125; 17/11/2021)vi Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	vi) Ordinary shares v) Ordinary shares
Number acquired	vi) 2,954,613 v) 2,954,613
Number disposed	vi) 2,954,613
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	vi) Non-cash, settlement of convertible note by MJ Life Sciences Pty Ltd - \$130,625 vi → v) Non-cash, distribution by MJ Life Sciences Pty Ltd to Sunset Capital Management Pty Ltd <Sunset Superfund> - \$130,625 (Net increase in Director interest of 2,954,613 ordinary shares valued at \$130,625).
No. of securities held after change	i. 11,200,000 ordinary shares ii. 5,800,000 ordinary shares iii. 538,230 ordinary shares iv. 1,642,105 ordinary shares v. 55,413,630 ordinary shares v. 8,000,000 options (\$0.03125; 17/11/2021) vi Nil
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	vi) Acquired via Off-market trade vi → v) Non-cash, distribution by MJ Life Sciences Pty Ltd to Sunset Capital Management Pty Ltd <Sunset Superfund> - \$130,625 (Net increase in Director interest of 2,954,613 ordinary shares).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELDA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	17 November 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Mal Washer Nominees Pty Ltd <Mal Washer Family A/C> (Director/Shareholder)
Date of change	1) 5 June 2019 2) 6 June 2019
No. of securities held prior to change	35,198,688 ordinary shares 6,000,000 options (\$0.03125; 17 November 2021)
Class	Ordinary shares
Number acquired	1) 2,686,000
Number disposed	2) 2,686,000
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	1) Non-cash, distribution by MJ Life Sciences Pty Ltd - \$118,750 2) \$104,754
No. of securities held after change	35,198,688 ordinary shares 6,000,000 options (\$0.03125; 17 November 2021)

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	1) Distribution by MJ Life Sciences Pty Ltd 2) Off market trade following cash election for Distribution by MJ Life Sciences Pty Ltd

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.